Aktis Oncology develops investigational miniprotein radioconjugates that deliver alpha radiation to solid tumors while rapidly clearing healthy tissues. A public clinical-stage company (Nasdaq: AKTS), Aktis is advancing AKY-1189 and AKY-2519. Its investigational therapies are not approved medicines.